Showing 1 - 6 results of 6 for search 'Serhat Sekmek', query time: 0.02s
Refine Results
-
1
-
2
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium by Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek, Hilal Karakas, Selver Isık, Murad Guliyev, Aysun Fatma Akkus, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yuksel Urun
Published 2025-05-01Get full text
Article -
3
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma by Omer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, Hilal Karakas, Serhat Sekmek, Saadet Sim, Selver Isık, Murat Günaltılı, Aysun Fatma Akkus, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Cengiz Karacin, Mehmet Ali Nahit Sendur, Nuri Karadurmus, Emre Yekedüz, Yüksel Ürün
Published 2025-07-01Get full text
Article -
4
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemot... by Sedat Yıldırım, Tugba Başoğlu, Akif Doğan, Goncagul Akdağ, Oguzcan Kınıkoğlu, Alper Topal, Ozkan Alan, Ali Alper Solmaz, Mustafa Gürbüz, Timucin Çil, Rumeysa Çolak, Mesut Yılmaz, Ali Kalem, Nadiye Sever, Nargiz Majıdova, Kubilay Karakoyun, Serhat Sekmek, Omer Saçlı, Melike Ozcelık, Deniz Işık, Heves Surmeli, Ozlem Nuray Sever, Hatice Odabas, Mahmut Emre Yıldırım, Nedim Turan
Published 2025-05-01Get full text
Article -
5
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study by Serhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, Cihan Erol, Fahriye Tugba Kos, Mehmet Ali Nahit Sendur, Yunus Emre Altıntas, Tugba Tuylu, Sedat Yildirim, Sedat Biter, Mehmet Mutlu Kıdı, Ertugrul Bayram, Nargiz Majidova, Ibrahim Vedat Bayoglu, Mehmetcan Atak, Kadriye Baskurt, Sinem Akbas, Ali Alkan, Ayberk Bayramgil, Ferit Aslan, Elif Sahin, Onur Yazdan Balcik, Ahmet Ziya Bayhan, Seray Saray, Erkan Arpaci, Yakup Ergun
Published 2024-11-01Get full text
Article -
6
Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study by Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık, Mustafa Şahbazlar, Mehmet Türker, Oğuzcan Kınıkoğlu, Tahir Yerlikaya, Gülhan Dinç, Ali Aytaç, Ziya Kalkan, Senar Ebinç, İlkay Gültürk, Merve Keskinkılıç, Zehra Sucuoğlu İşleyen, Dilek Çağlayan, Alper Türkel, Esra Aydın, Teoman Şakalar, Serhat Sekmek, Nilgün Yıldırım, Sinem Koçak, Kerem Okutur, Ahmet Özveren, Bengü Dursun, Sait Kitaplı, Orhan Önder Eren, İsmail Beypınar, İlhan Hacıbekiroğlu, Devrim Çabuk, Elanur Karaman, Ömer Acar, Semra Paydaş, Melek Karakurt Eryılmaz, Bilgin Demir, Zeynep Oruç, Mesut Yılmaz, Fatih Selçuk Biricik, Derya Kıvrak Salim, Özgür Tanrıverdi, Mutlu Doğan
Published 2025-03-01Get full text
Article